Background. As a cardiorenal syndrome, there is a dynamic interplay between the heart and the kidney. We conducted a prospective study to evaluate the prognostic impact of plasma B-type natriuretic peptide (BNP) level, a cardiac biomarker, on the long-term kidney prognosis in chronic kidney disease (CKD) patients. Methods. We prospectively enrolled 508 patients with CKD Stages 3, 4 and 5 not on dialysis, from a single nephrology department between 2004 and 2010. The exclusion criteria were over 90 years of age, malignancy, active infection, low cardiac ejection fraction and rapid progressive glomerulonephritis. Relationships between BNP and kidney end point [defined as doubling of baseline serum creatinine and end-stage kidney disease (ESKD) requiring kidney replacement therapy] were measured using Cox models for case-mix and laboratory variables. Results. The final analysis covered 485 participants with no loss to follow-up. The median follow-up period was 3.2 years. Two hundred and twenty-eight of the 485 patients reached ESKD requiring dialysis, and baseline serum creatinine levels doubled in another 31. The kidney end point was significantly poorer among patients with plasma BNP levels above, compared with below a cut-off value of 86.1 pg/mL indicated from receiver operating characteristic analysis. Multivariable Cox regression analysis identified the common logarithm BNP as a predictor of kidney end point (adjusted hazard ratio 1.78, 95% CI: 1.28-2.46, P < 0.01). Conclusions. Elevation of BNP level is associated with an increased risk for accelerated progression of CKD ultimately to ESKD. Monitoring the BNP level could be helpful in the management of combined heart and kidney disease.
Introduction
Chronic kidney disease (CKD) confers a markedly increased risk for developing cardiovascular disease (CVD), accelerating the presence of existing CVD and having an overall worse clinical prognosis [1] [2] [3] [4] .
As a method to monitor cardiac function of CKD patients, B-type natriuretic peptide (BNP) is a good candidate. BNP is secreted by left ventricular stretch and wall tension. Consequently, the level of BNP is high in patients with fluid overload (i.e. congestive heart failure) or left ventricular hypertrophy [5] . Nowadays, BNP is widely used as a marker for diagnosis and prognosis in primary and cardiological care settings [6] [7] [8] . There are two forms of BNP, N-terminal pro BNP (NT-pro BNP) and BNP. The perception is that the performance of NT-pro BNP as a diagnostic marker appears to be more adversely affected by kidney function than BNP when kidney function is severely deteriorated [9] . Hence, the role of BNP, not NT-pro BNP, should be examined in patients with CKD as a cardiac biomarker.
Levels of BNP are commonly elevated in patients with CKD, but the significance of this remains obscure, especially in patients before dialysis. Some evidence shows that a higher level of BNP is associated with lower cardiac function and a higher incidence of CVD events in patients before [10, 11] and on [12] [13] [14] dialysis.
As a cardiorenal syndrome, there is a dynamic interplay between the heart and the kidney. One important aspect is that decreased cardiac function could affect and determine kidney function [15] . However, as a predictor of kidney prognosis, the chronic impact of cardiac function is scarcely known. Thus, we conducted a prospective observational study to determine whether the level of BNP, a cardiac marker, predicts the progression of kidney disease in CKD patients before dialysis.
Materials and methods

Study population
We prospectively enrolled 508 consecutive patients with CKD Stages 3, 4 and 5, who were not on dialysis, from a single nephrology department at Rinku General Medical Center between August 2004 and October 2010.
Exclusion criteria included age >90 years (n = 1), malignancy (n = 7), active infection (n = 4), low cardiac ejection fraction (<40% determined by ultrasound) with regular follow-up by cardiologists (n = 4) and rapid progressive glomerulonephritis (n = 7) (Figure 1) . The study was approved by the institutional ethics committees of Rinku General Medical Center, and all patients provided written informed consent to participate in the study.
Blood sampling and measurements
Baseline blood samples from patients after an overnight fast were collected into plastic tubes with or without EDTA to prepare serum and plasma. The samples were immediately separated by centrifugation at 1500 g and 4°C for 10 min. BNP was measured using ARCHI-TECTRBNP-JP (Abbott Laboratories; CV <4% between 90 and 2000 pg/mL).
Definitions
Kidney function was evaluated from baseline data at the first visit to our outpatient clinic using the estimated glomerular filtration rate (eGFR) based on a newly developed equation for the Japanese population [16] . The formula is as follows: eGFR = 194 × serum creatinine (SCr) −1.094 × age
, where age is in years, SCr is in mg/dL and the GFR is in mL/ min/1.73 m 2 body surface area. The product of this equation for women was multiplied by a correction factor of 0.739. Patients were classified as having CKD, that is, CKD Stages 3, 4 or 5 (30 to <60, 15 to <30 or <15 mL/min/1.73 m 2 , respectively). Random urine samples (10 mL) were also collected at baseline to measure the ratio of urinary protein to creatinine. Other baseline variables included age, sex, diabetes defined according to the International Classification of Diseases, Tenth Revision (ICD-10) codes E10-E14, systolic blood pressure, diastolic blood pressure, albumin, calcium, phosphate, hemoglobin and use of the renin-angiotensin system inhibitor. Cardiovascular disease included sudden death (ICD-10 codes I46.1, I46.9), ischemic heart disease (ICD-10 codes I20-I25), heart failure (ICD-10 codes I50) and stroke (ICD-10 codes I60-I67).
End point
The primary end point defined as 'kidney end point' in this study was a loss of kidney function, taken as a combination of doubling of baseline serum creatinine and end-stage kidney disease (ESKD) requiring kidney replacement therapy. The secondary end point was a composite of kidney end point and all-cause of death.
Data collection
Patients received regular follow-up care in the outpatient ward. Data were collected from source documentation at the end of 2011. The baseline and follow-up data were collected from hospital medical records and discharge abstracts, outpatient visit records, contact with primary and dialysis care physicians and death certificates. End points were validated by at least two physicians. The follow-up of patients is available with accuracy because (i) this facility is the central hospital of the southern area of Osaka prefecture, and there is no other central hospital in this region, and (ii) regional partnership with the primary and dialysis care physicians has been well established.
Statistical analyses
Continuous variables are presented as medians and ranges or interquartile ranges (IQRs). Discrete data are given as counts and ratios (%). We compared categorical variables using the χ 2 test. We compared continuous data using the Mann-Whitney U-test and Kruskal-Wallis analysis, and analyzed trends in relationships between eGFR and BNP using the non-parametric Jonckheere-Terpstra test. Correlations between eGFR and BNP plasma concentrations were assessed using Spearman rank regression analysis. We performed univariate Cox proportional hazards analysis to identify the predictors of combined kidney endpoints. The proportionality of hazard assumption was confirmed graphically. We constructed multivariate Cox proportional hazard models to assess the independent prognostic roles of BNP adjusted with baseline characteristics (age, gender, diabetes mellitus, systolic blood pressure, diastolic blood pressure, eGFR, degree of proteinuria, serum albumin, calcium multiplied by phosphate and haemoglobin). Receiver operating characteristic (ROC) curves were drawn and the area under the curve was calculated. The optimal cut-off value of plasma BNP was selected when the product of sensitivity and specificity was maximized. Log-rank test was used to assess the equality of survival distribution stratified by the cut-off values. A two-sided P-value < 0.05 was considered significant. All data were analyzed using SPSS version 11.0 for Windows software.
Results
Data generated from 485 participants with a median followup period of 3.2 years (IQR, 1.8-5.0) were analyzed. None of the participants were lost to follow-up ( Figure 1 ). The baseline clinical and laboratory findings of the patients are shown in Table 1 . The primary causes of CKD were diabetic nephropathy (n = 157, 32.4%), chronic glomerular nephritis (n = 110, 22.7%), benign nephrosclerosis (n = 177, 36.5%), polycystic kidney disease (n = 11, 2.3%) and others. A history of cardiovascular disease was found in 143 patients. Baseline clinical characteristics of each CKD stage are shown in Table 2 . Patients with CKD Stage 4 and 5 patents frequently experienced CVD events (P < 0.01), a lower level of hemoglobin (P < 0.01) with a higher level of BNP (P < 0.01) and used RAS inhibitor more frequently (P < 0.01). The plasma BNP level ranged from 2.8 to 3100.0 pg/ mL [median (IQR) 77.2 (22.8-204.0)] and was correlated weakly with eGFR (r = −0.15, P < 0.01; Figure 2 ). During the follow-up period, 228 of 485 patients (14.5 per 100 patient-year) reached ESKD requiring dialysis, and 31 patients (1.97 per 100 patient-year) showed doubling of serum creatinine. In addition, 9 of the 485 patients (0.57 per 100 patient-year) died before reaching the kidney end point and 268 patients (17.1 per 100 patient-year) reached the secondary end point. The causes of death were cardiac infarction (n = 4), sudden death (n = 1), hepatic insufficiency (n = 1), sepsis (n = 1), respiratory failure (n = 1) and cachexia (n = 1).
The level of BNP was significantly higher in patients who reached the kidney end point than in those who did not [median (IQR) 116.0 (51.5-318.0) pg/mL versus 53.7 (24.8-126.0) pg/mL, P < 0.01] ( Table 3 ). The ROC analysis revealed that a BNP level of 86.1 pg/mL was an optimal cut-off for the kidney end point Survival curve analysis revealed that patients with above the cut-off BNP level (86.1 pg/mL) more frequently reached the kidney end point than those below (Figure 4) . The analyses using the cut-off BNP level for each CKD stage showed similar results (Supplementary data, Figure S1 ).
The results of the univariate Cox regression analysis indicated that the common logarithm of BNP is a predictor of both kidney end point [hazard ratio (HR): 1.76, 95% CI: 1.40-2.23, P < 0.01] and the secondary end point (HR: 1.78, 95% CI: 1.41-2.24, P < 0.01), together with eGFR, urinary protein, albumin, calcium multiplied by phosphate and hemoglobin (Table 4 ). The BNP level did not interact with either eGFR or urinary protein (P = 0.15 and 0.98 for the kidney endpoint and 0.23 and 0.91 for the composite endpoint). After adjustment for baseline covariates, the association of common logarithm BNP with both kidney (adjusted HR: 1.74, 95% CI: 1.28-2.46, P < 0.01; Table 4 ) and the secondary (adjusted HR: 1.74, 95% CI: 1.26-2.41, P < 0.01) end points remained significant.
Discussion
The present study found that plasma BNP level was a strong and independent predictor of CKD progression along with other classical predictors. Urinary protein, and kidney function itself (eGFR or serum creatinine) have historically served as classical predictors of kidney prognosis [17, 18] . The relatively specific cardiac biomarker BNP afforded an additional impact on kidney prognosis even in patients with CKD. Hence, the prognosis for the kidneys of patients with CKD seems to be determined by the kidney axis (urinary protein and eGFR) and the cardiac axis (BNP). Decreased kidney function in itself is not a major contributor to increase the BNP level. The data presented in Figure 2 and previous reports [5, 19] show low BNP levels in most patients with CKD despite having a decreased eGFR. Thus, diminished clearance alone seems to be an insufficient explanation for elevated BNP levels in patients with CKD. Rather, decreased cardiac function, such as left ventricular structural and functional alterations might increase the BNP level in patients with CKD [12] .
Some pathogenic factors may explain why the elevation of BNP level is associated with higher risk of developing ESKD in CKD patients. First, the elevation of BNP may indicate the existence of cardiac diseases. It is known that the prevalence of coronary artery stenosis and left ventricular hypertrophy is extremely high in CKD patients [3, 5, 20] . In addition, subclinical cardiac damage from silent myocardial ischemia or microinfarction and mild heart failure are strongly associated with patients with CKD [21, 22] . Such cardiac damage could compromise cardiac output resulting not only in high mortality [14, 23] but also low kidney blood flow, and thereby, leads to the final common pathway to ESKD [24] . Secondly, the elevated BNP level may represent volume overload [5] . Body fluid levels are difficult to assess and are empirically tailored by physicians to suit each individual. However, volume overload is a strong risk for congestive heart failure, and thereby, is a powerful determinant when starting dialysis therapy [25] . Close monitoring of body fluid status is mandatory for patients with advanced CKD because failure to do so results in acute cardiopulmonary decompensation. Therefore, measuring BNP in patients with CKD facilitates the comprehensive monitoring of decreased cardiac function and body fluid levels. Finally, the elevated BNP level might reflect the overactivity of neurological and humoral reactions. Excessive activation of the renin-angiotensin system [26] , endothelin secretion [27] and sympathetic nerve activity [28] is a frequent feature of patients with CKD that is associated with reactive oxygen species production [29] , which could result in cardiac stress and BNP secretion. In line with this, evidence from randomized clinical trials suggests that inhibition of the renin-angiotensin-aldosterone system can slow the progression of both kidney and cardiac damage in a selected high-risk population [30, 31] .
Therapies that decrease left ventricular wall tension, such as reducing body fluid volume using diuretics, dialysis, angiotensin-converting enzyme inhibition, erythropoietin or a beta-blockade, are of the most potential value in patients with CKD and elevated BNP levels. The causes of an increase in BNP, such as body fluid expansion due to kidney dysfunction, decreased cardiac function, activation of the renin-angiotensin system, production of reactive oxygen species, inflammation or sympathetic nervous system, are coincidentally the major cause of cardiorenal syndrome [32] . Consequently, monitoring BNP could facilitate the monitoring of the cardio-renal axis in patients with CKD [32] . The strategy to reduce the level of BNP in CKD patients would be fruitful, not only through the prevention of CVD events, but also through the prolongation of the initiation of dialysis therapy [33] . The association between cardiac biomarkers and a progressive decline in kidney function or cardiovascular events in patients with CKD has recently been investigated. Our data indicated that the optimal cut-off BNP level for kidney prognosis of patients with CKD is slightly higher than that described previously (86.1 versus 56 pg/mL) [34] . The major difference between the present and previous investigations is the study populations. Our study population comprised patients with CKD having a lower eGFR and patients with diabetes, and thereby, seems to be at higher risk for CVD events. On the other hand, we and others have previously demonstrated that the mortality of the nephrologist cohort is lower [35, 36] than that of population-based older cohorts [37] . One study [37] based on the population-based cohort showed the rate of kidney replacement therapy was much lower than mortality (19.9 and 45.7%, respectively, for 5-year ratios with CKD Stage 4). The major cause of death in this study is CVD, especially congestive heart failure and coronary artery disease. Because initiation of dialysis for volume overload improves cardiovascular care [38, 39] , the mortality was lower in our cohort than those of population-based cohorts at least partially due to the avoidance of the lethal CVD events. In line with this, monitoring BNP may facilitate the delivery to dialysis through the additional effect to nephrologist monitoring (i.e. medical interview, physical examination, chest X-ray and echocardiogram) on earlier detection of CVD events.
Monitoring BNP may have an additional effect to nephrologist monitoring (i.e. medical interview, physical examination, chest X-ray and echocardiogram) on earlier detection of CVD events.
Our study has some major limitations that must be addressed in further studies. First, we have no data about the structure of the heart, either at baseline or during follow-up. Secondly, the result of this study depends only on the baseline characteristics. The treatment by the nephrologists could reduce the level of BNP, however, we could not take the treatment effects into account. The treatment effects seem to affect patients with CKD Stage 3, whose BNP levels dramatically change as CKD stages advance. Together with the relatively small number of endpoints, this may have obscured the difference in the survival analysis. Thirdly, this is an observational study, and we could not determine whether the reduction of the BNP level could result in better kidney prognosis. In our experience, the reduction of the BNP level usually indicates better cardiac function or decreased body fluid level, and we assume that the reduction of the BNP level could lead to a better kidney prognosis. Further studies are needed to determine whether treatment to reduce BNP levels will result in improved kidney outcomes.
In conclusion, our data suggests that the elevated BNP level is a strong and independent predictor of the progression of CKD ultimately to ESKD. Monitoring BNP may be helpful to assess the cardiorenal syndrome in the management of patients with CKD.
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